This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Safety and Efficacy assessment of Monoprost� (unpr...
Clinical trial

Safety and Efficacy assessment of Monoprost� (unpreserved latanoprost) in comparison with Lumigan� 0.01 % and Lumigan� 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan� 0.01 % with ocular surface intoler

Read time: 1 mins
Last updated:8th Aug 2013
The primary objective is to demonstrate the superiority of Monoprost� versus Lumigan� 0.01% and Lumigan� 0.03% UD in term of safety with respect to the assessment of conjunctival hyperaemia in the worse eye at Day 84. The conjunctival hyperaemia will be scored using the photographic McMonnies scale (0 to 5). The worse eye is defined as the eligible eye with the highest hyperaemia score on the McMonnies scale at D0.
Category Value
Study start date 2013-08-08

View full details